USPTO Examiner BAEK BONG SOOK - Art Unit 1611

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18944456AQUEOUS SUSPENSION SUITABLE FOR ORAL ADMINISTRATIONNovember 2024June 2025Allow710YesNo
18670599METHOD OF TREATMENT OF DEPRESSED PATIENTS WITH POOR COGNITION AND SELECTION OF OTHER PATIENTS BENEFITING FROM A BENZYLPIPERAZINE-AMINOPYRIDINE AGENTMay 2024March 2025Abandon1010NoNo
18615512COMPOSITIONS AND METHODS FOR ADMINISTERING PALTUSOTINE TO PATIENTS WITH HEPATIC IMPAIRMENTMarch 2024September 2024Allow610YesNo
18588191QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASEFebruary 2024June 2024Allow400YesNo
18426972AQUEOUS SUSPENSION SUITABLE FOR ORAL ADMINISTRATIONJanuary 2024August 2024Allow610YesNo
18405189NOVEL SHORT-ACTING PSYCHOACTIVE COMPOUNDS OF THE MDMA CLASSJanuary 2024June 2025Abandon1810NoNo
18404037USP9X InhibitorsJanuary 2024July 2024Allow600YesNo
18524381GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOFNovember 2023July 2024Allow811YesNo
18384489NEEM FOR TREATMENT OF RLSOctober 2023May 2024Allow700YesNo
18491200Inhibition of Lysine Demethylase 1 (Lsd1) Induces Differentiation of Hair CellsOctober 2023February 2025Abandon1610NoNo
18485086USE OF DEXPRAMIPEXOLE FOR THE TREATMENT OF MODERATE TO SEVERE ASTHMAOctober 2023September 2024Abandon1110NoNo
18485082USE OF DEXPRAMIPEXOLE FOR THE TREATMENT OF MODERATE TO SEVERE ASTHMAOctober 2023August 2024Abandon1010NoNo
18376346HETEROCYCLYLAMINES AS PI3K INHIBITORSOctober 2023August 2024Allow1101YesNo
182402001,3-BENZOTHIAZOL-2-YL-N'-[(3-PHENYLPROP-2-ENOYL)OXY]ETHANIMIDAMIDE AS AN ANTICANCER AND ANTIMICROBIAL COMPOUNDAugust 2023November 2023Allow300YesNo
18240076PHARMACEUTICAL COMPOSITIONS COMPRISING (S)-4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-4-YL)OXY)METHYL)BENZYL)PIPERAZIN-1-YL)-3-FLUOROBENZONITRILE AND METHODS OF USING THE SAMEAugust 2023April 2024Allow700YesNo
182392731,3-BENZOTHIAZOL-2-YL-N'-[(NAPHTHALENE-1-CARBONYL)OXY]ETHANIMIDAMIDE AS AN ANTITUMOR AND ANTIMICROBIAL COMPOUNDAugust 2023November 2023Allow200YesNo
18455757COMBINATIONS COMPRISING BREXPIPRAZOLE OR A SALT THEREOF AND A SECOND DRUG FOR USE IN THE TREATMENT OF A CNS DISORDERAugust 2023January 2025Abandon1610NoNo
18229474QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASEAugust 2023January 2024Allow610NoNo
18209334NOVEL SHORT-ACTING PSYCHOACTIVE COMPOUNDS OF THE MDMA CLASSJune 2023December 2023Allow610YesNo
18326505REELIN/VEGF-C PRODUCTION/ACTIVATION PROMOTER AND SKIN EXTERNAL COMPOSITION USING THE SAMEMay 2023June 2024Allow1320YesNo
18199634QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASEMay 2023September 2023Allow410YesNo
18198373PHARMACEUTICAL COMPOSITIONS AND ORAL DOSAGE FORMS OF KETAMINE DERIVATIVESMay 2023May 2025Allow2420NoNo
18313991HOST DEFENSE PROTEIN (HDP) MIMETICS FOR PROPHYLAXIS AND/OR TREATMENT OF INFLAMMATORY DISEASES OF THE GASTROINTESTINAL TRACTMay 2023January 2025Abandon2010NoNo
18136484STABILIZATION OF EPINEPHRINE FORMULATIONSApril 2023April 2025Allow2420YesNo
18300504AQUEOUS SUSPENSION SUITABLE FOR ORAL ADMINISTRATIONApril 2023October 2023Allow610YesNo
18095161USP9X INHIBITORSJanuary 2023March 2024Abandon1410NoNo
18059350METHODS AND DEVICES FOR TREATMENT OF EYELID PTOSISNovember 2022August 2023Allow811YesNo
17988230USP9X INHIBITORSNovember 2022March 2023Allow400YesNo
17985504PHARMACEUTICAL COMPOSITION COMPRISING OXIDIZABLE BIPHENOL AND MANGANESE PORPHYRIN, AND METHOD OF USING THE SAMENovember 2022October 2024Allow2311YesNo
17958169THERAPEUTIC USES OF L-4-CHLOROKYNURENINESeptember 2022February 2025Abandon2911NoNo
17935408SMALL MOLECULE ANTIVIRAL DRUG TREATMENT FOR HUMAN PAPILLOMAVIRUS INFECTIONSSeptember 2022August 2023Allow1111YesNo
17949300EXTENDED RELEASE COMPOSITIONS COMPRISING PYRIDOSTIGMINESeptember 2022September 2023Abandon1210NoNo
17896483METHODS OF ADMINISTERING GAMMA-HYDROXYBUTYRATE COMPOSITIONS WITH DIVALPROEX SODIUMAugust 2022August 2023Abandon1210YesNo
17887049PHARMACEUTICAL COMPOSITIONS AND ORAL DOSAGE FORMS OF KETAMINE DERIVATIVESAugust 2022February 2023Allow611YesNo
17871922BUFFER- AND CHELATOR-FREE, STABLE OPHTHALMOLOGICAL COMPOSITIONS OF KETOROLAC AND PHENYLEPHRINE AND APPLICATIONS THEREOFJuly 2022July 2023Abandon1210NoNo
17866942HETEROCYCLYLAMINES AS PI3K INHIBITORSJuly 2022July 2023Allow1210YesNo
17851165Treatment of Dermal Cytokine Storm SyndromesJune 2022July 2024Abandon2440NoYes
17782850SPIRO COMPOUND SERVING AS ERK INHIBITOR, AND APPLICATION THEREOFJune 2022April 2025Allow3400YesNo
17824993AQUEOUS SUSPENSION SUITABLE FOR ORAL ADMINISTRATIONMay 2022January 2023Allow810YesNo
17748475BUPROPION AS A MODULATOR OF DRUG ACTIVITYMay 2022August 2022Allow310YesNo
17772878SYNERGISTIC NUTRITIONAL COMPOSITIONS FOR TREATING CEREBROVASCULAR DISEASESApril 2022August 2023Allow1520YesNo
17721827BUPROPION AS A MODULATOR OF DRUG ACTIVITYApril 2022July 2022Allow300YesNo
17717516BUPROPION AS A MODULATOR OF DRUG ACTIVITYApril 2022July 2022Allow300YesNo
17716796BUPROPION AS A MODULATOR OF DRUG ACTIVITYApril 2022July 2022Allow300YesNo
17713872FORMULATIONS OF FOSAPREPITANT AND APREPITANTApril 2022August 2024Abandon2820NoYes
17657832BUPROPION AS A MODULATOR OF DRUG ACTIVITYApril 2022June 2022Allow200YesNo
17712970BUPROPION AS A MODULATOR OF DRUG ACTIVITYApril 2022June 2022Allow300YesNo
17705834Coated Particles and Their UsesMarch 2022January 2023Allow1001YesNo
17705930BUPROPION AS A MODULATOR OF DRUG ACTIVITYMarch 2022June 2022Allow200YesNo
17591621Conjugates And Conjugating Reagents Comprising A Linker That Includes At Least Two (-CH2-CH2-O-) Units In A RingFebruary 2022August 2023Allow1911YesNo
17579069SMALL MOLECULE ANTIVIRAL DRUG TREATMENT FOR HUMAN PAPILLOMAVIRUS INFECTIONSJanuary 2022February 2023Allow1320YesNo
17621567RHO KINASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOFDecember 2021March 2025Allow3900YesNo
17456459BUPROPION AS A MODULATOR OF DRUG ACTIVITYNovember 2021February 2022Allow300YesNo
17456146BUPROPION AS A MODULATOR OF DRUG ACTIVITYNovember 2021March 2022Allow300YesNo
17612757N-CONTAINING HETEROARYL DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCERNovember 2021February 2025Allow3900YesNo
17454110PHARMACEUTICALLY ACCEPTABLE SALTS OF MESDOPETAM AND USES THEREOFNovember 2021November 2023Abandon2410NoNo
175186082-[Thiophen-2-yl)formamido]-N-(phenyl)-2-methylpropanamide derivatives and the use therof as medicamentNovember 2021February 2023Allow1501YesNo
17498507BUPROPION AS A MODULATOR OF DRUG ACTIVITYOctober 2021September 2023Abandon2310NoNo
17486634COMPOSITIONS COMPRISING TACROLIMUS FOR THE TREATMENT OF INTRAOCULAR INFLAMMATORY EYE DISEASESSeptember 2021May 2025Abandon4440NoNo
17406895METHOD FOR TREATING ATHLETES SUBJECT TO PATHOLOGICAL CARDIAC HYPERTROPHY BY ADMINISTERING NIGELLA SATIVAAugust 2021May 2024Abandon3321YesNo
17405429BUPROPION AS A MODULATOR OF DRUG ACTIVITYAugust 2021April 2022Allow810YesNo
17431336METHODS AND COMPOSITIONS FOR TREATING LYSOSOMAL STORAGE DISORDERS: AMBROXOL AS TREATMENT AGENT FOR MUCOPOLYSACCHARIDOSES III (SANFILIPPO SYNDROME)August 2021May 2025Allow4511YesNo
17430903SUBSTITUTED AMIDE COMPOUNDS USEFUL AS FARNESOID X RECEPTOR MODULATORSAugust 2021February 2025Allow4210YesNo
17401642QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASEAugust 2021July 2023Allow2311YesNo
17402419COMPOSITIONS FOR AND METHODS OF INHIBITING SARS-COV2 INFECTIONAugust 2021February 2024Allow3011YesNo
17401371QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASEAugust 2021May 2023Allow2111YesNo
17430409PYRROLIDINE OREXIN RECEPTOR AGONISTSAugust 2021April 2025Allow4421YesNo
17400359DOSAGE FORM FOR VAPORIZATION AND SMOKINGAugust 2021July 2023Allow2300YesNo
17398156METHOD AND COMPOSITION FOR TREATING CORONA VIRUS, INFLUENZA, AND ACUTE RESPIRATORY DISTRESS SYNDROMEAugust 2021June 2025Abandon4741NoNo
17395222BUPROPION AS A MODULATOR OF DRUG ACTIVITYAugust 2021April 2022Allow810YesNo
17394398Method for the augmentation of substance abuse therapies using cannabinoid formulationsAugust 2021November 2023Abandon2710NoNo
17427112IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOFJuly 2021September 2024Allow3701YesNo
17426898FIBROSIS DRUGJuly 2021September 2024Allow3820YesNo
17425461CARBAMATE DERIVATIVES AND USES THEREOFJuly 2021May 2025Abandon4601NoNo
17366007COMPOSITIONS AND METHODS FOR INDUCING BIOLOGICAL MIMICRY IN A MAMMAL FOR THE PREVENTION AND/OR TREATMENT OF COVID-19 AND OTHER DISEASESJuly 2021September 2023Abandon2601NoNo
17420181TESOFENSINE FOR REDUCTION OF BODY WEIGHT IN PRADER-WILLI PATIENTSJuly 2021May 2025Abandon4611NoNo
17418353INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 AND USES THEREOFJune 2021December 2024Allow4211YesNo
17357388METHOD OF TREATING PATIENTS INFECTED WITH SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2)June 2021January 2023Allow1910NoNo
17417182HETEROCYCLIC DERIVATIVES AS NAV1.7 AND NAV1.8 BLOCKERSJune 2021July 2024Allow3701YesNo
17309712ESTROGEN RECEPTOR ANTAGONISTJune 2021October 2024Allow4010YesNo
17413815METHODS FOR THE TREATMENT OF DEPRESSIONJune 2021December 2024Abandon4210NoNo
17299137Functionalised Amine Derivatives as IL-17 ModulatorsJune 2021May 2025Allow4821YesNo
17336613SUBLINGUAL FORMULATION FOR HYPOTENSION AND SYNCOPEJune 2021October 2024Abandon4131NoNo
17335772METAL DI-AMINO ACID CHELATES OR METAL TRI-AMINO ACID CHELATESJune 2021January 2025Abandon4431NoNo
17296764Inhibition of Lysine Demethylase 1 (Lsd1) Induces Differentiation of Hair CellsMay 2021December 2023Abandon3110NoNo
17296553COMPOSITIONS FOR TREATMENT OF SYMPHYSIOLYSISMay 2021December 2024Abandon4321NoNo
172966014-AMINO OR 4-ALKOXY-SUBSTITUTED ARYL SULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELSMay 2021October 2024Allow4111NoNo
17296617PHARMACEUTICAL FORMULATIONS COMPRISING AN AMINOINDANE COMPOUNDMay 2021June 2025Abandon4921NoNo
17293755METHOD OF TREATING REFRACTORY EPILEPSY SYNDROMES USING FENFLURAMINE ENANTIOMERSMay 2021January 2024Abandon3210NoNo
17246400METHODS OF PROPHYLAXIS AND TREATMENT OF COVID-19 USING AZOXIMER BROMIDEApril 2021April 2023Abandon2410NoNo
17290012COMBINATION OF M-OPIOID RECEPTOR (MOR) MODULATORS FOR PREVENTING AND TREATING PAIN, SUICIDALITY AND MENTAL DISORDERSApril 2021June 2024Abandon3811NoNo
17289601INJECTABLE FORMULATIONS OF ANESTHETICS FOR ANY PATHOLOGICAL PAINApril 2021February 2025Allow4631YesNo
17287837COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITYApril 2021January 2024Abandon3301NoNo
17286155METHODS OF TREATING CENTRAL NERVOUS SYSTEM DISORDERSApril 2021October 2024Abandon4201NoNo
17231455METHODS OF ADMINISTERING GAMMA-HYDROXYBUTYRATE COMPOSITIONS WITH DIVALPROEX SODIUMApril 2021August 2023Abandon2811YesNo
17309017COMPOSITIONS AND METHODS FOR ACTIVATING NRF2-DEPENDENT GENE EXPRESSIONApril 2021March 2024Allow3511YesNo
17284131ESKETAMINE FOR USE IN TREATING MAJOR DEPRESSIVE DISORDERApril 2021March 2025Allow4720YesNo
17224231COMPOSITIONS AND METHODS FOR THE PROPHYLAXIS AND/OR TREATMENT OF VIRAL INFECTIONS OR CONDITIONS ASSOCIATED THEREWITHApril 2021February 2024Abandon3420NoNo
17215292HAIR COMPOSITIONS AND METHODS OF USE THEREOFMarch 2021August 2022Allow1700YesNo
17278393POSITIVE ALLOSTERIC MODULATORS OF GABAA RECEPTORMarch 2021October 2023Allow3101YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner BAEK, BONG-SOOK.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
4
Examiner Affirmed
4
(100.0%)
Examiner Reversed
0
(0.0%)
Reversal Percentile
0.0%
Lower than average

What This Means

With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.

Strategic Value of Filing an Appeal

Total Appeal Filings
26
Allowed After Appeal Filing
1
(3.8%)
Not Allowed After Appeal Filing
25
(96.2%)
Filing Benefit Percentile
9.5%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 3.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner BAEK, BONG-SOOK - Prosecution Strategy Guide

Executive Summary

Examiner BAEK, BONG-SOOK works in Art Unit 1611 and has examined 385 patent applications in our dataset. With an allowance rate of 55.1%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 27 months.

Allowance Patterns

Examiner BAEK, BONG-SOOK's allowance rate of 55.1% places them in the 10% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by BAEK, BONG-SOOK receive 1.75 office actions before reaching final disposition. This places the examiner in the 52% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by BAEK, BONG-SOOK is 27 months. This places the examiner in the 55% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +76.4% benefit to allowance rate for applications examined by BAEK, BONG-SOOK. This interview benefit is in the 99% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 23.2% of applications are subsequently allowed. This success rate is in the 22% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 17.1% of cases where such amendments are filed. This entry rate is in the 12% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 92% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 55.6% of appeals filed. This is in the 22% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.

Petition Practice

When applicants file petitions regarding this examiner's actions, 39.4% are granted (fully or in part). This grant rate is in the 37% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 2.1% of allowed cases (in the 78% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.